Seres Therapeutics, Inc. (MCRB): Roger Pomerantz , President and CEO of Seres Therapeutics, Inc. sold 56,789 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $29.65 per share for a total value of $1,692,704.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 30, 2016, Eric D. Shaff (CFO and EVP) sold 4,533 shares at $29.54 per share price.On Jun 29, 2016, John G. Aunins (Chief Technology Officer & EVP) sold 9,390 shares at $27.23 per share price.Also, On Jun 6, 2016, Roger Pomerantz (President and CEO) sold 74,049 shares at $32.39 per share price.On Jun 6, 2016, David N Cook (Chief Scientific Officer & EVP) sold 8,000 shares at $31.00 per share price.
Seres Therapeutics Inc: On Friday, Jul 1, 2016 heightened volatility was witnessed in Seres Therapeutics Inc which led to swings in the share price. The shares opened for trading at $28.8 and hit $30.02 on the upside , eventually ending the session at $29.93, with a gain of 3.03% or 0.88 points. The heightened volatility saw the trading volume jump to 2,44,425 shares. The 52-week high of the share price is $52 and the company has a market cap of $1,183 M . The 52-week low of the share price is at $21.12.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.